| Literature DB >> 33195032 |
Iogann Tolbatov1, Damiano Cirri2, Lorella Marchetti2, Alessandro Marrone1, Cecilia Coletti1, Nazzareno Re1, Diego La Mendola3, Luigi Messori4, Tiziano Marzo3,5, Chiara Gabbiani2, Alessandro Pratesi2.
Abstract
Au(PEt3)I (AF-I hereafter), the iodide analog of the FDA-approved drug auranofin (AF hereafter), is a promising anticancer agent that produces its pharmacological effects through interaction with non-genomic targets such as the thioredoxin reductase system. AF-I is endowed with a very favorable biochemical profile showing potent in vitro cytotoxic activity against several cancer types including ovarian and colorectal cancer. Remarkably, in a recent publication, some of us reported that AF-I induces an almost complete and rapid remission in an orthotopic in vivo mouse model of ovarian cancer. The cytotoxic potency does not bring about highly severe side effects, making AF-I very well-tolerated even for higher doses, even more so than the pharmacologically active ones. All these promising features led us to expand our studies on the mechanistic aspects underlying the antitumor activity of AF-I. We report here on an integrated experimental and theoretical study on the reactivity of AF-I, in comparison with auranofin, toward relevant aminoacidic residues or their molecular models. Results point out that the replacement of the thiosugar moiety with iodide significantly affects the overall reactivity toward the amino acid residues histidine, cysteine, methionine, and selenocysteine. Altogether, the obtained results contribute to shed light into the enhanced antitumoral activity of AF-I compared with AF.Entities:
Keywords: 31PNMR; DFT; ESI-MS; auranofin; cancer; gold; metal-based anticancer drugs; protein metalation
Year: 2020 PMID: 33195032 PMCID: PMC7531625 DOI: 10.3389/fchem.2020.00812
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Figure 1Chemical structures of Auranofin (AF) and Iodo(triethylphosphine)gold(I) (AF-I).
Results obtained by 31PNMR experiments for the incubation at different time intervals (t = 0 and t = 24 h) of AF and AF-I with His, Met, Cys, or Sec.
| AF | Au(PEt3)-S-DTT | Au(PEt3)-Se-CH2-R | ||||||
| AF-I | Au(PEt3)-S-CH2-R | Au(PEt3)-S-CH2-R | Au(PEt3)-S-DTT | Au(PEt3)-Se-CH2-R | ||||
No adduct formation.
Adduct with dithiothreitol (DTT);
Adduct with Se of selenocysteine;
Adduct with S of cysteine (Cirri et al., .
.
R= –CH(NH.
Figure 2ATR-FTIR spectra of Cys (dashed line) and Cys/AF adducts (solid line).
Figure 3ESI mass spectrum of auranofin (10−5 M) incubated for 24 h at 37 °C with cysteine (1:1 metal to amino acid ratio), in ammonium acetate buffer 500 mM pH=6.8 in presence of 50% MeOH.
Scheme 1Reaction scheme and considered nucleophiles. Attacking atoms in bold.
Assessment of five density functionals for the geometry optimization via comparison of experimental and calculated values for structural parameters of AF and AF-I complexes (Figure 1).
| wB97X | 2.30 | 2.34 | 178.8 | 103.1 | 2.30 | 2.62 | 179.4 | 8.35 |
| M06L | 2.30 | 2.37 | 178.5 | 98.3 | 2.30 | 2.64 | 180.0 | 9.20 |
| B3LYP | 2.32 | 2.36 | 178.5 | 103.7 | 2.32 | 2.65 | 179.8 | 8.90 |
| CAM-B3LYP | 2.30 | 2.34 | 178.3 | 103.7 | 2.30 | 2.62 | 179.6 | 8.05 |
| B3LYP-D3 | 2.30 | 2.37 | 177.8 | 99.1 | 2.31 | 2.65 | 179.9 | 8.10 |
| Exp [39, 71] | 2.26 | 2.29 | 173.6 | 105.6 | 2.27 | 2.59 | 178.9 | - |
All distances are in angstroms and all angles in degrees. No reactant-adducts for the reactions of AF/AF-I with deprotonated cysteine and selenocysteine could be optimized.
Figure 4Representation of the experimentally characterized structures of AF and AF-I complexes, the respective crystallographic cartesian coordinates are extrapolated from (Hill and Sutton, 1980; Marzo et al., 2017). All distances are in angstroms, all angles in degrees.
Enthalpies and Gibbs free energies for reaction of AF/AF-I with various biomolecular targets in solution.
| His | AF | 9.4 | 9.6 | 11.3 | 25.6 | 10.0 | 14.4 |
| AF-I | 5.7 | 9.8 | 5.1 | 16.3 | 3.3 | 7.4 | |
| Met | AF | 14.8 | 16.4 | 18.7 | 32.4 | 18.8 | 23.6 |
| AF-I | 11.2 | 16.6 | 5.9 | 17.8 | 5.2 | 10.1 | |
| Cys | AF | 18.1 | 17.4 | 17.2 | 26.7 | 16.2 | 18.7 |
| AF-I | 14.4 | 17.6 | 5.9 | 15.5 | 5.7 | 7.7 | |
| Sec | AF | 15.5 | 16.8 | 17.9 | 27.2 | 16.6 | 19.2 |
| AF-I | 11.9 | 17.0 | 5.9 | 16.3 | 6.0 | 9.0 | |
| Cys− | AF | −2.4 | −3.9 | 11.7 | 21.3 | – | – |
| AF-I | −6.0 | −3.7 | 2.8 | 12.0 | – | – | |
| Sec− | AF | −0.9 | −2.5 | 3.4 | 21.2 | – | – |
| AF-I | −4.4 | −2.2 | 2.1 | 14.1 | – | – | |
No reactant-adducts for the reactions of AF/AF-I with deprotonated cysteine and selenocysteine could be optimized.
Figure 5Transition states for thiosugar or iodide substitution by all considered amino acids.
Figure 6Reaction profiles for AF and AF-I interacting with neutral His and Met and anionic Cys− and Sec− nucleophiles.